Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK138D1 in Advanced Solid Tumors
NCT07281326Phase 1Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK138D1 in solid tumor cancer, sponsored by Akeso, Inc. Primary endpoints: Adverse Events at 2 years and Dose-Limiting Toxicity at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
AK138D1
03
Conditions
solid tumor cancer
Beyond the preview
Go deeper on NCT07281326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281326.